Pharmaceuticals — Clinical Development
Establish the product safety and efficacy through each phase of clinical development. New scripts and features designed especially to meet Clinical Data Integration Standards Consortium (CDISC) standards make JMP ideal as a review tool for clinical data. Integrate with SAS Clinical Life Sciences products such as SAS Drug Development and SAS Clinical Data Integration.
Benefits
- Clinical Trials
- New Drug Application (NDA) Submission
- Analyze mortality and serious adverse events using a combination of JMP platforms, including the Categorical platform, Distribution platform, Tree Map and the Data Filter.
- Find laboratory measure outliers, then point and click to see the data behind them.
- Monitor exposure data with safety data to determine the maximally tolerated dose (MTD).
- Use the Distribution platform to analyze and summarize exposure data, employing the histogram to quickly create dosing groups.
- Identify drug-drug and drug-disease interactions by using the table update function to merge Submission Data Tabulation Model (SDTM) domains and model them using the Partition platform.
- Explore drug effects through sub-group analysis, using the Graph Builder with the Data Filter.
- Analyze highly specific efficacy endpoint data.
- Identify trial participants who drop out early and validate disposition data.
- Shorten time spent in the FDA review cycle.
- Take advantage of compatibility with the SDTM and the Analysis Data Model (ADaM).
- Copy and paste your results into a PDF and send them directly to the FDA at the New Drug Application (NDA) submission point.
- Create Patient Profiles in JMP for interactive analysis and exploration.
JMP and JMP Genomics software offer interactive analysis for every stage of the drug discovery and development process.
Featured Webcast
Watch Using CDISC Models to Analyze Drug Safety Data, presented by JMP and SAS.
